Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's product candidate Delpacibart etedesiran is for the treatment of myotonic dystrophy type 1 and is currently in phase 3 trial. Its other products in pipeline include Delpacibart zotadirsen for the treatment of duchenne muscular dystrophy, which is under phase 2 clinical development trial; and Delpacibart braxlosiran for the treatment of facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare genetic cardiomyopathies for PRKAG2 syndrome and PLN cardiomyopathy. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Atrium Therapeutics, Inc.

Vanguard ETFs are often known for their low costs and long-term stability, but not all of them get the attention they deserve. Some lesser-known Va...

3 Vanguard ETFs Flying Under the Radar with 20% Upside

Bernstein analyst Courtney Breen maintained a Hold rating on Moderna yesterday and set a price target of $45.00. The company’s shares closed yester...

Moderna (MRNA) Receives a Hold from Bernstein

An announcement from Alterity Therapeutics ( ($AU:ATH) ) is now available. Alterity Therapeutics has scheduled its next Annual General Meeting for ...

Alterity Therapeutics Sets 2026 AGM Date and Director Nomination Deadline

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pyxis Oncology (PYXS), Moderna (MRNA) and Eli Lill...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Pyxis Oncology (PYXS), Moderna (MRNA) and Eli Lilly & Co (LLY)

Moderna shares ($MRNA) surged by more than 14% to about $176 on Monday afternoon. This came after the U.S. pharma and biotech firm announced a key ...

Why Is Moderna Stock (MRNA) Soaring Today, September 21?

Alterity Therapeutics ( ($AU:ATH) ) has shared an update. Alterity Therapeutics, a clinical-stage biotechnology company, develops disease-modifying...

Alterity Therapeutics to Spotlight MSA Program at ASX SMIDcaps Conference

Eterna Therapeutics ( ($ERNA) ) has provided an announcement. On September 16, 2026, Ernexa Therapeutics Inc. made available a new corporate fact s...

Eterna Therapeutics Updates Investors With New Corporate Materials

Eterna Therapeutics ( ($ERNA) ) has issued an update. On September 14, 2026, Ernexa Therapeutics Inc. appointed Robert J. Spiegel, M.D. to its boar...

Eterna Therapeutics appoints independent director Robert J. Spiegel

Alterity Therapeutics ( ($AU:ATH) ) has issued an update. Alterity Therapeutics has applied for quotation of 50,000 new ordinary fully paid shares ...

Alterity Therapeutics Seeks Quotation for New ASX Shares

The latest update is out from TransCode Therapeutics ( ($RNAZ) ). On September 10, 2026, TransCode Therapeutics said Chief Financial Officer and di...

TransCode Therapeutics Announces CFO Resignation and Interim Appointment

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Moderna (MRNA) and BioNano Genomics (BNGO). Modern...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Moderna (MRNA) and BioNano Genomics (BNGO)

Evercore ISI analyst Cory Kasimov maintained a Hold rating on Moderna today and set a price target of $80.00. According to TipRanks, Kasimov is a 5...

Evercore ISI Sticks to Its Hold Rating for Moderna (MRNA)

Alterity Therapeutics ( ($AU:ATH) ) has shared an update. Alterity Therapeutics Limited, an ASX-listed Australian biopharmaceutical company, has is...

Alterity Therapeutics Issues 8.4 Million Shares Under Underwriting Deal

Alterity Therapeutics ( ($AU:ATH) ) has issued an update. Alterity Therapeutics Limited has applied for quotation of 8,400,000 new ordinary fully p...

Alterity Therapeutics Seeks ASX Quotation for 8.4 Million New Shares

Cathie Wood-led ARK Invest made several notable trades on Friday, September 4, with Robinhood Markets ($HOOD), an online brokerage and financial-se...

Cathie Wood Buys $3.6M of HOOD, Sells $2.9M of 2 High-Growth Stocks – September 5

Alterity Therapeutics ( ($AU:ATH) ) has provided an update. Alterity Therapeutics, a clinical-stage biotechnology company developing disease-modify...

Alterity Therapeutics to Spotlight MSA Program at Cantor Global Healthcare Conference

Alterity Therapeutics ( ($AU:ATH) ) has provided an announcement. Alterity Therapeutics has reported a change in the securities interests of direct...

Alterity Therapeutics Updates Director Equity Holdings After Option Expiry

Alterity Therapeutics ( ($AU:ATH) ) has shared an announcement. Alterity Therapeutics has disclosed a change in director Peter Marks’ interests in ...

Alterity Director Peter Marks Converts Options, Lifts Equity Stake

The pharma company’s share price soared on news of a cancer drug breakthrough. 


Moderna Stock (MRNA) Was the Best Performer in August

Alterity Therapeutics ( ($AU:ATH) ) has provided an update. Alterity Therapeutics has filed its Annual Report on Form 20-F, including audited conso...

Alterity Therapeutics Files 2026 Annual Report and XBRL Data with SEC

Alterity Therapeutics ( ($AU:ATH) ) has provided an update. Alterity Therapeutics has entered into an underwriting agreement with MST Financial Ser...

Alterity Taps Underwritten ATHO Options to Fund ATH434 MSA Program

Alterity Therapeutics ( ($AU:ATH) ) has shared an announcement. Alterity Therapeutics has lodged its updated corporate governance statement for the...

Alterity Therapeutics Files Updated Corporate Governance Statement with ASX

An update from Alterity Therapeutics ( ($AU:ATH) ) is now available. Alterity Therapeutics reported a sharp increase in interest income to A$1.72 m...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RNA	$8.29	+1.22%	221.43K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RNA	$8.29	+1.2%	221.43K
3
4
5
6

RNA

Get Atrium Therapeutics, Inc. Data in Excel

Get Atrium Therapeutics, Inc. Data in Excel